ArticleOncology letters2025
Machine learning-based radiomics models for the prediction of metachronous liver metastases in patients with colorectal cancer: A multimodal study.
Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Multimodal prediction of metachronous liver metastasis in stage I-III colorectal cancer patients: multicenter cohort study employing machine learning.Abdominal radiology (New York) · 2026Article
- Comparison of Radiomic Features from Different MRI Sequences for Predicting Synchronous Liver Metastases after Rectal CancerCurrent medical imaging · 2026Article
- Improving early liver metastasis detection in colorectal cancer using a weighted ensemble of ResNet50 and swin transformer: a KHCC study.Frontiers in big data · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of the present study was to investigate whether a multimodal radiomics model powered by machine learning could accurately predict the occurrence of metachronous liver metastasis (MLM) in patients with colorectal cancer (CRC). A total of 157 patients diagnosed with CRC between 2010 and 2020 were retrospectively included in the present study; of these patients, 67 patients developed liver metastases within 2 years of treatment, while the remaining patients (n=90) did not. Radiomics features were extracted from annotated MR images of the tumor and portal venous phase CT images of the liver in each patient. Subsequently, machine learning-based radiomics models were developed and integrated with the clinical features for MLM prediction, employing Least Absolute Shrinkage and Selection Operator and Random Forest algorithms. The performance of the models were evaluated using the receiver operating characteristic curve analysis, while the clinical utility was measured using the decision curve analysis. A total of 922 and 1,082 radiomics features were extracted from the MR and CT images of each patient, respectively, which quantified the intensity, shape, orientation and texture of the tumor and liver. The mean area under the curve (AUC) values for the prediction of MLM were 0.80, 0.68 and 0.82 for the CT, MRI and merged models, respectively. For the clinical and clinical-merged models, the AUC values were 0.62 and 0.75, respectively. There was no significant difference between the CT model and the merged model (P>0.05). In conclusion, the preliminary results of the present study demonstrated the utility of machine learning-based radiomics models in the prediction of MLM in patients with CRC. However, further research is warranted to explore the potential of multimodal fusion models, due to the minimal improvement observed in diagnostic performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.